Loading
A phase 2 trial of Enfortumab vedotin and Pembrolizumab in advanced solid tumours, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) is a phase 2 interventional study registered as NCT04225117 by Astellas Pharma Global Development, Inc., with 329 participants enrolled, started 2020-03-10 and due to reach its primary completion in 2025-02-25. Interventions recorded: enfortumab vedotin and pembrolizumab. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
329 enrolled.
95% CI 6.49 to 29.46; Figures from the ClinicalTrials.gov results section (first posted 2026-04-13), not from a publication · 95% CI 8.60 to 34.12 · 95% CI 0.11 to 21.95 · 95% CI 6.81 to 30.70 · 95% CI 12.59 to 38.77 · 95% CI 2.66 to 22.62 · 95% CI 8.19 to 32.71
Source95% CI 24.20 to 55.50; Figures from the ClinicalTrials.gov results section (first posted 2026-04-13), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessmentprimary | Cohort 1: HR+/HER2- Breast Cancer | 45 | 15.6% | - | - | link |
| Cohort 2: TNBC Cancer | 42 | 19% | ||||
| Cohort 3: Squamous NSCLC | 23 | 4.3% | ||||
| Cohort 4: Non-squamous NSCLC | 43 | 16.3% | ||||
| Cohort 5: Head and Neck Cancer | 46 | 23.9% | ||||
| Cohort 7: EAC | 42 | 9.5% | ||||
| Cohort 8: ESCC | 44 | 18.2% | ||||
| Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessmentprimary | Cohort 9: HNSCC | 41 | 39% | - | - | link |
Shares Enfortumab vedotin, Astellas, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Astellas, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.